Very encouraging for the Rett's families and potentially other application to other neuro conditions moving forward, but still not convinced the results are enough for a really favourable deal or a fire under the SP. They are still learning much about the pharmacokinetics of the medication, but are making positive advancements.
"Since it shows the potential of neurobiologically-based drugs for the treatment of Rett syndrome and other neurodevelopmental disorders" is potentially a game changer, but this requires much further study. Will pharma pay up for this potential combined with the what we know in Rett's now, or will they want further insight...
Very encouraging for the Rett's families and potentially other...
-
- There are more pages in this discussion • 63 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$20.22 |
Change
0.240(1.20%) |
Mkt cap ! $2.584B | |||
| Open | High | Low | Value | Volume |
| $20.11 | $20.34 | $19.63 | $8.874M | 441.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1010 | $20.22 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $20.23 | 1443 | 2 |
View Market Depth
| Last trade - 16.10pm 25/06/2024 (20 minute delay) ? |
| NEU (ASX) Chart |